Modifying a cancer drug has created a new agent for multi-resistant infections

-

Researchers from the Technical University of Munich (TUM) and the Helmholtz Center for Infection Research (HZI) in Braunschweig have modified an approved cancer drug to create an agent that is effective at treating multi-drug-resistant infections.

The agent has so far only been tested in mice, but the researchers are planning to optimize it further so it can enter the clinical development phase.
The urgent need for new antibiotics

Antibiotic-resistant bacteria are increasingly causing severe and deadly infections. Methicillin-resistant Staphylococcus aureus (MRSA) causes a persistent infection that can sometimes be resistant to various different antibiotics, and new drugs that are effective against it are urgently needed.

Director of the Infection Immunology Research Group at HZI, Eva Medina, says the industrial development of new antibiotics is stalling and not keeping pace with the spread of antibiotic resistance.


A new approach to developing antibiotics
One promising approach is testing the potential effects of drugs that have already been approved as treatments. For the current study, Stephen Sieber from TUM and colleagues decided to investigate a group of human proteins called kinases, for which many inhibitors are already available.

The team modified the active ingredient in a kinase inhibitor used to treat cancer that is also effective against MRSA to increase the inhibitor’s antibiotic effect.

They managed to develop a molecule that was ten times more potent than the original agent.

Sieber says the chemical changes made to the agent have meant it no longer binds to human kinases, but instead acts specifically against bacterial targets.

The new molecule targets MRSA in various unconventional ways, and the team decided to focus on two potential new targets. One was the agent’s inhibition of a protein the bacteria requires for energy metabolism, and the other was its activity on the cell wall.

Unlike established antibiotics such as penicillin and methicillin, which directly disrupt the formation of the bacterial cell wall, the new molecule acts indirectly. It increases the production of proteins involved in cell wall thickness, which causes the cell to burst.

The agent was effective in a mouse model
In mice, the new agent proved effective at destroying MRSA in a range of tissues. The researchers found that while staphylococci quickly became resistant to other antibiotics, they did not become resistant to this new one.

Medina and colleague Katharina Rox also demonstrated that the agent has favorable pharmacological properties. For instance, it can be taken as a tablet, and it stays stable in the body for a number of hours.

Head of the HZI research group, Dietmar Pieper, says that MRSA infections are often chronic since the bacteria can become dormant and that another benefit of the new agent is that it “even kills these.”

The team now plans to develop the agent further so that it can enter clinical development.
Source:

From cancer medication to antibiotic. Eurekalert. Available from: https://www.eurekalert.org/emb_releases/2019-12/tuom-fcm121219.php

Join the conference for discussion, visit our Conference Website: http://antibiotics.alliedacademies.com/

Contact: Erika Madison
What's app: 44 1829 580014
Office Phone: 44 203 769 1755 [Mention Helen/ Erika Madison]
Mail ID: antibiotics@alliedforums.org
LinkedIn: Erika Madison
Twitter: @MicrobioEvents
You comments are welcomed**


Comments

Post a Comment

Popular posts from this blog

Proper disposal of leftover medication can help reduce antibiotic resistance

-
Image
Proper disposal of leftover medication, particularly antibiotics and opioids, can help reduce antibiotic resistance, prevent children from being poisoned and stop the misuse of addiction-forming drugs. But a telephone survey conducted by researchers at UC San Francisco found that fewer than half of California pharmacies provided disposal instructions meeting U.S. Food and Drug Administration guidelines, and just 10 percent followed the FDA's preferred recommendation to take back unused medications from their customers. Over a two-month period in early 2018 researchers posing as parents of children who had recently had surgery spoke to employees at nearly 900 pharmacies in California and asked them what to do with two leftover medications: the antibiotic Bactrim (sulfamethoxazole-trimethoprim), and liquid Hycet (hydrocodone-acetaminophen), a pain reliever containing an opioid compound. Neither medication should be left in the medicine cabinet, since the antibiotics could be
Read more

Antibiotic resistance is a natural phenomenon amplified by inappropriate uses..

-
Image
Antimicrobial resistance is the phenomenon whereby bacteria exposed to the same antibiotic for a prolonged period of time mutate and become resistant, which makes their control, difficult, if not impossible, with current treatments. This phenomenon stems from the process of natural selection. From the discovery of the first antibiotics, Alexander Fleming, discoverer of penicillin, had already revealed this major risk to their effectiveness for health in the long term. However, it has been seriously amplified by an excessive and inconsiderate use of antibiotics for 50 years, in both human and animal health. It is estimated, for example, that about 80% of the antibiotics sold in the United   States are destined for animal husbandry. The first bacteria resistant to antibiotics appeared as early as the 1960s, very soon after the first treatments were marketed. Since then, antibiotic-resistant bacteria have been multiplying. Many bacteria that cause serious infections in humans, s
Read more

Bacteria can survive under antibiotic exposure by developing a biological timer

-
Image
Hebrew University of Jerusalem researchers showed that when exposed to repeated cycles of antibiotics, bacteria evolved a new adaptation by remaining dormant for the treatment period. The results show for the first time that bacteria can develop a biological timer to survive under antibiotic exposure. With this new understanding of how bacteria evolve survival strategies, scientists could develop new approaches for slowing the evolution of antibiotic resistance. The ability of microorganisms to overcome antibiotic treatments is one of the top concerns of modern medicine. The effectiveness of many antibiotics has been reduced by bacteria's ability to rapidly evolve and develop strategies to resist antibiotics. Bacteria achieve this by specific mechanisms that are tailored to the molecular structure or function of a particular antibiotic. For example, bacteria would typically develop drug resistance by evolving a mutation that breaks down the drug. Researchers at the Hebrew Uni
Read more